Abstract
Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Adjuvants, Immunologic / adverse effects
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Viral / blood*
-
Cross Reactions*
-
Female
-
Hemagglutination Inhibition Tests
-
Humans
-
Immunization, Secondary / adverse effects
-
Immunization, Secondary / methods*
-
Influenza A Virus, H5N1 Subtype / immunology*
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects
-
Influenza Vaccines / immunology*
-
Male
-
Middle Aged
-
Polysorbates / administration & dosage*
-
Polysorbates / adverse effects
-
Squalene / administration & dosage*
-
Squalene / adverse effects
-
Young Adult
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Influenza Vaccines
-
MF59 oil emulsion
-
Polysorbates
-
Squalene